Operaciones Pluri Inc. - PLUR CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.0424 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.030779% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | -0.013666% | ||||||||
Horario tarifa nocturna | 22:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Cierre previo* | 1.0088 |
Abrir* | 1.0188 |
Cambio de 1 año* | -42.11% |
Rango del día* | 1.0188 - 1.0488 |
Rango de 52 semanas | 0.65-2.21 |
Volumen medio (10 días) | 31.83K |
Volumen medio (3 meses) | 1.46M |
Capitalización de mercado | 35.27M |
Ratio P/E | -100.00K |
Acciones en circulación | 32.66M |
Ingresos | 321.00K |
EPS | -1.12 |
Dividendo (Rendimiento %) | N/A |
Beta | 1.60 |
Próxima fecha de resultados | N/A |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Feb 7, 2023 | 1.0088 | -0.0400 | -3.81% | 1.0488 | 1.0488 | 1.0088 |
Feb 6, 2023 | 1.0288 | 0.0000 | 0.00% | 1.0288 | 1.0288 | 1.0088 |
Feb 3, 2023 | 1.0587 | -0.0600 | -5.36% | 1.1187 | 1.1287 | 1.0587 |
Feb 2, 2023 | 1.1187 | 0.0200 | 1.82% | 1.0987 | 1.1187 | 1.0787 |
Jan 27, 2023 | 1.1187 | -0.0299 | -2.60% | 1.1486 | 1.1586 | 1.1087 |
Jan 26, 2023 | 1.1287 | 0.0100 | 0.89% | 1.1187 | 1.1287 | 1.1187 |
Jan 25, 2023 | 1.0887 | 0.0000 | 0.00% | 1.0887 | 1.0887 | 1.0887 |
Jan 24, 2023 | 1.1586 | 0.0000 | 0.00% | 1.1586 | 1.1686 | 1.1586 |
Jan 20, 2023 | 1.1586 | -0.0400 | -3.34% | 1.1986 | 1.1986 | 1.1586 |
Jan 19, 2023 | 1.2286 | 0.0200 | 1.65% | 1.2086 | 1.2585 | 1.1686 |
Jan 18, 2023 | 1.2785 | 0.0599 | 4.92% | 1.2186 | 1.2785 | 1.2186 |
Jan 17, 2023 | 1.2585 | 0.0799 | 6.78% | 1.1786 | 1.3285 | 1.1786 |
Jan 13, 2023 | 1.2086 | 0.1399 | 13.09% | 1.0687 | 1.3984 | 1.0687 |
Jan 12, 2023 | 1.0288 | 0.0000 | 0.00% | 1.0288 | 1.0687 | 1.0288 |
Jan 11, 2023 | 1.0088 | -0.0200 | -1.94% | 1.0288 | 1.0288 | 1.0088 |
Jan 9, 2023 | 1.0288 | 0.0300 | 3.00% | 0.9988 | 1.0588 | 0.9988 |
Jan 6, 2023 | 0.9986 | 0.0435 | 4.55% | 0.9551 | 1.0288 | 0.9551 |
Jan 5, 2023 | 0.9550 | -0.0299 | -3.04% | 0.9849 | 0.9850 | 0.9489 |
Jan 4, 2023 | 0.9987 | 0.0039 | 0.39% | 0.9948 | 0.9988 | 0.9948 |
Jan 3, 2023 | 0.9916 | 0.0067 | 0.68% | 0.9849 | 0.9985 | 0.9788 |
Pluri Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Ingresos totales | 2.847 | 0 | 0.05 | 0.054 | 0.023 | 0 |
Ingresos | 2.847 | 0 | 0.05 | 0.054 | 0.023 | 0 |
Coste de los ingresos, total | 0.1 | 0 | 0.002 | 0.002 | 0 | 0 |
Beneficio bruto | 2.747 | 0 | 0.048 | 0.052 | 0.023 | 0 |
Gastos totales de explotación | 26.166 | 28.019 | 33.781 | 35.586 | 29.499 | 50.623 |
Gastos de venta/general/administración Gastos, total | 6.486 | 6.927 | 11.193 | 9.157 | 7.922 | 20.557 |
Investigación y desarrollo | 20.85 | 21.972 | 24.478 | 12.841 | 21.643 | 13.47 |
Depreciation / Amortization | 2.006 | 2.029 | 1.893 | 1.841 | 1.453 | 1.252 |
Other Operating Expenses, Total | -3.276 | -2.909 | -3.785 | 11.745 | -1.519 | 15.344 |
Ingresos de explotación | -23.319 | -28.019 | -33.731 | -35.532 | -29.476 | -50.623 |
Ingresos por intereses (gastos), netos No operativos | 0.109 | 0.272 | 8.542 | 0.105 | 0.356 | 0.781 |
Otros, netos | -0.036 | -0.067 | -0.937 | 0.12 | -0.032 | -0.023 |
Ingresos netos antes de impuestos | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Ingresos netos después de impuestos | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Beneficio neto antes de partidas extra. Elementos | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Ingresos netos | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Beneficio neto diluido | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Promedio ponderado de acciones diluidas | 7.9548 | 8.74262 | 10.5877 | 1.23329 | 18.1973 | 28.1136 |
BPA diluido sin partidas extraordinarias | -2.92226 | -3.18143 | -2.46759 | -28.6283 | -1.602 | -1.77369 |
Dividends per Share - Common Stock Primary Issue | 0 | |||||
BPA normalizado diluido | -2.85237 | -3.12149 | -2.38995 | -28.1158 | -1.5688 | -1.74709 |
Q3 2021 | Q4 2021 | Q1 2021 | Q2 2021 | Q3 2022 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0 | 0 | 0.234 |
Ingresos | 0 | 0 | 0.234 | ||
Coste de los ingresos, total | 0 | 0 | |||
Beneficio bruto | 0 | 0 | |||
Gastos totales de explotación | 14.225 | 14.587 | 11.441 | 10.795 | 10.709 |
Gastos de venta/general/administración Gastos, total | 6.559 | 6.102 | 5.088 | 4.288 | 4.553 |
Investigación y desarrollo | 7.824 | 8.507 | 6.391 | 6.541 | 6.273 |
Other Operating Expenses, Total | -0.158 | -0.022 | -0.038 | -0.034 | -0.117 |
Ingresos de explotación | -14.225 | -14.587 | -11.441 | -10.795 | -10.475 |
Ingresos por intereses (gastos), netos No operativos | -0.029 | 0.019 | 0.009 | -0.145 | 0.557 |
Ingresos netos antes de impuestos | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Ingresos netos después de impuestos | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Beneficio neto antes de partidas extra. Elementos | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Ingresos netos | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Beneficio neto diluido | -14.254 | -14.568 | -11.432 | -10.94 | -9.918 |
Promedio ponderado de acciones diluidas | 29.6172 | 31.6441 | 32.0008 | 32.1363 | 32.2616 |
BPA diluido sin partidas extraordinarias | -0.48127 | -0.46037 | -0.35724 | -0.34042 | -0.30742 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
BPA normalizado diluido | -0.48127 | -0.46037 | -0.35724 | -0.34042 | -0.30742 |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Activo Corriente | 35.596 | 29.016 | 32.036 | 26.371 | 48.461 | 67.371 |
Efectivo e inversiones a corto plazo | 32.208 | 26.106 | 29.9 | 23.705 | 45.784 | 64.95 |
Efectivo y Equivalentes | 6.223 | 4.707 | 8.821 | 4.106 | 8.27 | 31.241 |
Inversiones a corto plazo | 25.985 | 21.399 | 21.079 | 19.599 | 37.514 | 33.709 |
Total deudores, neto | 2.481 | 1.174 | 0.847 | 1.421 | 1.61 | 1.49 |
Accounts Receivable - Trade, Net | 2.251 | 1.036 | 0.69 | 1.243 | 1.248 | 1.108 |
Prepaid Expenses | 0.3 | 0.882 | 0.602 | 0.532 | 0.445 | 0.333 |
Other Current Assets, Total | 0.607 | 0.854 | 0.687 | 0.713 | 0.622 | 0.598 |
Total Assets | 45.941 | 37.534 | 38.96 | 31.31 | 65.532 | 93.538 |
Property/Plant/Equipment, Total - Net | 9.216 | 7.277 | 5.678 | 3.838 | 3.775 | 2.227 |
Property/Plant/Equipment, Total - Gross | 17.183 | 16.507 | 16.893 | 17.004 | 18.437 | 18.259 |
Accumulated Depreciation, Total | -7.967 | -9.23 | -11.215 | -13.166 | -14.662 | -16.032 |
Long Term Investments | 0.363 | 0.403 | 0.383 | 0.398 | 12.653 | 23.269 |
Other Long Term Assets, Total | 0.766 | 0.838 | 0.863 | 0.703 | 0.643 | 0.671 |
Total Current Liabilities | 5.775 | 5.414 | 8.548 | 8.158 | 7.987 | 11.517 |
Accounts Payable | 2.705 | 1.966 | 3.261 | 2.281 | 1.968 | 2.526 |
Accrued Expenses | 2.819 | 3.106 | 4.164 | 5.637 | 5.893 | 8.951 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.251 | 0.342 | 1.123 | 0.24 | 0.126 | 0.04 |
Total Liabilities | 7.785 | 7.283 | 10.453 | 9.489 | 9.431 | 36.387 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 23.85 |
Other Liabilities, Total | 2.01 | 1.869 | 1.905 | 1.331 | 1.444 | 1.02 |
Total Equity | 38.156 | 30.251 | 28.507 | 21.821 | 56.101 | 57.151 |
Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | ||
Additional Paid-In Capital | 198.432 | 217.822 | 244.203 | 272.824 | 336.257 | 387.172 |
Retained Earnings (Accumulated Deficit) | -161.757 | -189.571 | -215.697 | -251.004 | -280.156 | -330.021 |
Unrealized Gain (Loss) | 1.48 | 1.48 | 8.44 | |||
Other Equity, Total | 0 | 0.519 | -8.44 | |||
Total Liabilities & Shareholders’ Equity | 45.941 | 37.534 | 38.96 | 31.31 | 65.532 | 93.538 |
Total Common Shares Outstanding | 8.0269 | 9.69388 | 11.3566 | 15.0829 | 25.4927 | 31.9578 |
Long Term Debt | 23.85 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Activo Corriente | 49.82 | 67.371 | 62.826 | 60.153 | 64.313 |
Efectivo e inversiones a corto plazo | 47.37 | 64.95 | 60.671 | 58.183 | 61.98 |
Efectivo y Equivalentes | 12.265 | 31.241 | 14.611 | 18.715 | 23.791 |
Inversiones a corto plazo | 35.105 | 33.709 | 46.06 | 39.468 | 38.189 |
Other Current Assets, Total | 2.45 | 2.421 | 2.155 | 1.97 | 2.333 |
Total Assets | 79.174 | 93.538 | 83.747 | 81.184 | 79.127 |
Property/Plant/Equipment, Total - Net | 2.713 | 2.227 | 1.749 | 9.331 | 9.14 |
Long Term Investments | 25.937 | 23.269 | 18.483 | 10.965 | 4.235 |
Other Long Term Assets, Total | 0.704 | 0.671 | 0.689 | 0.735 | 1.439 |
Total Current Liabilities | 9.916 | 11.517 | 10.365 | 9.595 | 7.822 |
Accounts Payable | 2.11 | 2.526 | 3.723 | 4.058 | 3.942 |
Accrued Expenses | 5.613 | 6.575 | 6.642 | 5.537 | 3.88 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.193 | 2.416 | |||
Total Liabilities | 11.038 | 36.387 | 34.84 | 41.344 | 41.034 |
Total Long Term Debt | 0 | 23.85 | 23.444 | 23.158 | 22.924 |
Other Liabilities, Total | 1.122 | 1.02 | 1.031 | 8.591 | 8.238 |
Total Equity | 68.136 | 57.151 | 48.907 | 39.84 | 38.0933 |
Additional Paid-In Capital | 383.589 | 387.172 | 390.36 | 392.233 | 400.351 |
Retained Earnings (Accumulated Deficit) | -315.453 | -330.021 | -341.453 | -352.393 | -362.258 |
Total Liabilities & Shareholders’ Equity | 79.174 | 93.538 | 83.747 | 81.184 | 79.1273 |
Total Common Shares Outstanding | 31.7402 | 31.9578 | 32.0969 | 32.2251 | 32.3424 |
Total deudores, neto | 0 | ||||
Accounts Receivable - Trade, Net | 0 | ||||
Current Port. of LT Debt/Capital Leases | 0 | ||||
Long Term Debt | 23.85 | 23.444 | 23.158 | 22.924 | |
Common Stock | 0.00032 | 0.00032 | |||
Other Equity, Total | -0.00032 | ||||
Minority Interest | 2.05 |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Ingresos netos/Línea de salida | -23.246 | -27.814 | -26.126 | -35.307 | -29.152 | -49.865 |
Efectivo de actividades de explotación | -18.522 | -21.611 | -21.38 | -29.453 | -26.369 | -30.91 |
Efectivo de actividades de explotación | 2.15 | 2.177 | 2.018 | 1.962 | 1.57 | 1.37 |
Partidas no monetarias | 3.498 | 4.174 | -1.025 | 5.146 | 2.562 | 13.968 |
Cash Taxes Paid | 0.066 | 0.028 | 0.027 | 0.01 | 0.01 | |
Cambios en el capital circulante | -0.924 | -0.148 | 3.753 | -1.254 | -1.349 | 3.617 |
Efectivo de actividades de inversión | 1.312 | 4.355 | 5.681 | 1.17 | -30.458 | -7.265 |
Gastos de capital | -1.75 | -0.378 | -0.342 | -0.239 | -0.27 | -0.373 |
Otras partidas de flujo de caja de inversión, total | 3.062 | 4.733 | 6.023 | 1.409 | -30.188 | -6.892 |
Efectivo procedente de actividades de financiación | 0.807 | 15.797 | 19.921 | 23.582 | 60.87 | 61.402 |
Emisión (retiro) de acciones, neto | 0.807 | 15.728 | 19.833 | 23.475 | 60.87 | 36.953 |
Variación neta de la tesorería | -16.403 | -1.459 | 4.222 | -4.701 | 4.043 | 22.609 |
Elementos de flujo de caja de financiación | 0.069 | 0.088 | 0.107 | 0 | ||
Emisión (amortización) de deuda, neta | 24.449 | |||||
Efectos del cambio de divisas | -0.618 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -35.297 | -49.865 | -11.432 | -22.372 | -32.29 |
Cash From Operating Activities | -21.313 | -30.91 | -8.789 | -18.652 | -28.074 |
Cash From Operating Activities | 1.034 | 1.37 | 0.337 | 0.664 | 0.915 |
Non-Cash Items | 10.382 | 13.968 | 3.188 | 6.1 | 7.782 |
Cash Taxes Paid | 0.008 | ||||
Changes in Working Capital | 2.568 | 3.617 | -0.882 | -3.044 | -4.481 |
Cash From Investing Activities | -12.057 | -7.265 | -7.24 | 7.075 | 14.738 |
Capital Expenditures | -0.331 | -0.373 | -0.015 | -0.044 | -0.081 |
Other Investing Cash Flow Items, Total | -11.726 | -6.892 | -7.225 | 7.119 | 14.819 |
Cash From Financing Activities | 36.992 | 61.402 | 0 | 0 | 7.5 |
Issuance (Retirement) of Stock, Net | 36.992 | 36.953 | 0 | 0 | 0 |
Net Change in Cash | 3.622 | 22.609 | -16.62 | -12.616 | -6.908 |
Issuance (Retirement) of Debt, Net | 24.449 | ||||
Foreign Exchange Effects | -0.618 | -0.591 | -1.039 | -1.072 | |
Financing Cash Flow Items | 7.5 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
Yanay (Yaky) | Individual Investor | 3.2937 | 1075620 | 396790 | 2022-12-22 | LOW |
Regals Capital Management, L.P. | Investment Advisor | 3.2824 | 1071938 | 1071938 | 2022-01-24 | |
Aberman (Zalman) | Individual Investor | 2.5434 | 830604 | -2000 | 2022-12-20 | LOW |
Slager (David M) | Individual Investor | 1.8774 | 613100 | 613100 | 2022-01-24 | HIGH |
Nia Impact Capital | Investment Advisor | 0.4071 | 132947 | -318394 | 2022-09-30 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.3235 | 105657 | -174105 | 2022-09-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.3197 | 104400 | -2900 | 2022-09-30 | HIGH |
Bridgeway Capital Management, LLC | Investment Advisor | 0.3142 | 102600 | -10000 | 2022-09-30 | LOW |
Nikko Asset Management Americas, Inc. | Investment Advisor/Hedge Fund | 0.2574 | 84056 | -20865 | 2021-12-31 | LOW |
Franco-Yehuda (Chen) | Individual Investor | 0.225 | 73466 | 6875 | 2022-12-21 | LOW |
Green Alpha Advisors, LLC | Investment Advisor | 0.1794 | 58603 | 2377 | 2022-12-31 | HIGH |
Values First Advisors, Inc. | Investment Advisor | 0.1398 | 45653 | -2677 | 2022-12-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.1211 | 39544 | 0 | 2022-12-31 | LOW |
Jane Street Capital, L.L.C. | Research Firm | 0.1102 | 35986 | -46524 | 2022-09-30 | HIGH |
Group One Trading, L.P. | Research Firm | 0.0877 | 28638 | -5900 | 2022-09-30 | HIGH |
Zürcher Kantonalbank (Asset Management) | Bank and Trust | 0.0842 | 27497 | -137 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.0771 | 25169 | 0 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 0.0625 | 20412 | -120303 | 2022-09-30 | HIGH |
Archford Capital Strategies, LLC | Investment Advisor | 0.0401 | 13091 | 0 | 2022-12-31 | LOW |
Hightower Advisors, LLC | Investment Advisor | 0.0367 | 11985 | -26000 | 2022-09-30 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com GroupTraders
Clientes activos mensualmente
Volumen mensual de inversión
Retiros por mes
Calculadora de trading
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Pluri Inc. Company profile
Sobre Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. desarrolla productos de terapia celular basados en la placenta para el tratamiento de múltiples enfermedades isquémicas, inflamatorias y hematológicas. Las principales indicaciones de la empresa son la isquemia crítica de las extremidades, la recuperación tras una intervención quirúrgica por fractura del cuello del fémur y el síndrome de radiación agudo. Sus operaciones se centran en la investigación, el desarrollo, los ensayos clínicos y la fabricación de terapias celulares y tecnologías relacionadas. Los productos de la empresa incluyen PLX-PAD y PLX R18. Las células PLX de la empresa son células estromales adherentes (ASC) que se expanden mediante un proceso tridimensional (3D). El sistema utiliza un andamio sintético para crear un entorno 3D artificial en el que pueden crecer las células estromales derivadas de la placenta. Los productos PLX de la empresa se administran con una aguja y una jeringa estándar. Los productos PLX de la empresa están en fase de desarrollo clínico para múltiples indicaciones, como las enfermedades cardiovasculares, ortopédicas, pulmonares y de salud femenina.
Industry: | Biotechnology & Medical Research (NEC) |
MATAM Advanced Technology Park
Building #5
3508409
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com